Lyra Therapeutics (LYRA) Misses Q2 EPS by 534c

Lyra Therapeutics (NASDAQ: LYRA) reported Q2 EPS of ($5.51), $5.34 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $183 thousand versus the consensus estimate of $242 thousand.

For earnings history and earnings-related data on Lyra Therapeutics (LYRA) click here.

You May Also Be Interested In

• Stifel on Eos Energy Enterprises (EOSE) amid 10% gain: 'we view the collaboration with Google as a positive step for EOSE'
• Advent International proposes $1.02-per-share buyout of Definitive Healthcare
• DA Davidson Reiterates Buy Rating on ACI Worldwide (ACIW) as Deal to Acquire Cranium Ventures Announced